share_log

Senti Biosciences Analyst Ratings

Benzinga Analyst Ratings ·  Jan 27, 2023 10:30
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/27/2023 54.64% Morgan Stanley $7.5 → $3 Maintains Equal-Weight
12/16/2022 JP Morgan Initiates Coverage On → Neutral
10/07/2022 286.6% Morgan Stanley → $7.5 Initiates Coverage On → Equal-Weight
09/29/2022 260.82% B of A Securities → $7 Initiates Coverage On → Buy
09/23/2022 518.56% Chardan Capital → $12 Initiates Coverage On → Buy

What is the target price for Senti Biosciences (SNTI)?

The latest price target for Senti Biosciences (NASDAQ: SNTI) was reported by Morgan Stanley on January 27, 2023. The analyst firm set a price target for $3.00 expecting SNTI to rise to within 12 months (a possible 54.64% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Senti Biosciences (SNTI)?

The latest analyst rating for Senti Biosciences (NASDAQ: SNTI) was provided by Morgan Stanley, and Senti Biosciences maintained their equal-weight rating.

When is the next analyst rating going to be posted or updated for Senti Biosciences (SNTI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Senti Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Senti Biosciences was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.

Is the Analyst Rating Senti Biosciences (SNTI) correct?

While ratings are subjective and will change, the latest Senti Biosciences (SNTI) rating was a maintained with a price target of $7.50 to $3.00. The current price Senti Biosciences (SNTI) is trading at is $1.94, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment